Low-dose vemurafenib monotherapy in <i>BRAF<sup>V600E</sup></i>-mutated Erdheim-Chester disease
Gordon Ruan, Antonious Hazim, Jithma P. Abeykoon, Caleb Scheckel, Robert Vassallo, Jay H. Ryu, W. Oliver Tobin, Matthew J. Koster, N. Nora Bennani, Karen L. Rech, Jason R. Young, Mithun Vinod Shah, Gaurav Goyal, Ronald S. Go
Abstract
Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm derived from the macrophage/dendritic cell lineage and harbors the BRAFV600E mutation in 50–60% of patients [1]. The U.S. Food and Drug ...
Topics & Concepts
VemurafenibErdheim–Chester diseaseMedicineV600ECancer researchDiseaseDermatologyInternal medicineMutationMetastatic melanomaMelanomaChemistryHistiocytosisBiochemistryGeneHistiocytic Disorders and TreatmentsEosinophilic Disorders and SyndromesMast cells and histamine